Loading data for ZYME — first visit, this takes a few seconds.

Zymeworks Inc. (ZYME)

NasdaqGS: ZYME · Precio en tiempo real · USD

28.27

-0.74 (-2.55%)

Al cierre: Sep 02, 2026, 3:59 PM

31.00

-0.16%

Fuera de horario: 7:30 PM

Alerta

Alert

El precio, las cifras principales y las últimas noticias, en un solo sitio.

-2.55% (1D)

Precio de compra	20.34
Capitalización de mercado	2.22B
Ingresos (TTM)	37.1M
Beneficio neto (TTM)	-150M
	1.15
	-2.02
	n/a
	26.62
P/B (TTM)	27.60
P/S (TTM)	59.80
Fecha de resultados	Nov 5, 2026

Precio de venta	28.54
Volumen	542,057
Volumen medio (20D)	637,758
Abierto	28.91
Anterior Cerrar	29.01
Rango del día	28.18 - 28.91
Rango de 52 semanas	13.60 - 30.62
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de ZYME

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to th...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Apr 28, 2017

Empleados 231

Bolsa de Valores NasdaqGS

Símbolo bursátil ZYME

Sitio web https://www.zymeworks.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Zymeworks fueron 105.97M, un aumento de 38.87% en comparación con 76.3M del año anterior. Las ganancias fueron -81.13M, una disminución de -33.88%.

Estados financieros

Sorpresa de resultados

Zymeworks ha publicado sus resultados trimestrales en Aug 6, 2026:

Ingresos de $4.59M falla las estimaciones por $0, con -90.58% Disminución interanual.
EPS de -0.62 falla las estimaciones por -0.03, con -2166.67% Disminución interanual.

Próxima publicación de resultados

Está previsto que Zymeworks Inc. publique sus resultados el Nov 5, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Por qué se movió el precio

Noticias

5 días hace · Simply Wall St.

Zymeworks (ZYME), What Is Behind The Renewed Attention?

Why Zymeworks Stock Is Back in Focus After FDA Approval Zymeworks (ZYME) moved into the spotlight after the FDA approved zanidatamab for first line HER2 positive gastroesophageal adenocarcinoma, putti...

6 días hace · Simply Wall St.

Is Zymeworks (ZYME) Stock Fully Priced After Its 301% Run?

Zymeworks stock has delivered very strong returns over the past three years, yet the broader valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Recen...

6 días hace · Benzinga

Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Jazz Pharmaceuticals plc’s two Ziihera-containing combination regimens as first-line treatments for adults with unresectable locally ad...

1 semana hace · Stocktwits

SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?

SJM raised its annual outlook following a quarterly earnings beat, while ZYME gained on price-target hikes tied to Ziihera’s FDA approval.

1 semana hace · Zacks

JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer

Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.

Página 1 de 2

Zymeworks Inc. (ZYME)